Nintedanib: A New Hope for Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
| dc.contributor.advisor | Golden, Grace | |
| dc.contributor.advisor | Paty, Carol | |
| dc.contributor.author | Roldan, Yessica | |
| dc.date.accessioned | 2023-08-18T15:59:22Z | |
| dc.date.available | 2023-08-18T15:59:22Z | |
| dc.date.issued | 2023 | |
| dc.description | 25 pages | en_US |
| dc.description.abstract | Scleroderma, or systemic sclerosis, is a rare autoimmune disease group that causes hardening and tightening of the skin. Systemic diffuse scleroderma is a subtype that can also damage internal organs. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a condition in which the interstitial lung tissue becomes inflamed and undergoes irreversible fibrosis and is the leading cause of death for patients with diffuse scleroderma. Its progression is generally measured by the decline in forced vital capacity. Nintedanib (NIN) is a promising antifibrotic treatment that is FDA approved to treat SSc-ILD. This is a literature review in which three studies were selected to investigate the effectiveness and safety of NIN in comparison to an impactful precursor study. The selected studies indicate that NIN is associated with diminished lung progression and potentially reduces lung attenuation. NIN is an effective and safe treatment that can improve a SSc-ILD patient’s quality of life and extend their lifespan. | en_US |
| dc.identifier.orcid | 0009-0007-0965-9644 | |
| dc.identifier.uri | https://hdl.handle.net/1794/28715 | |
| dc.language.iso | en_US | |
| dc.publisher | University of Oregon | |
| dc.rights | CC BY-NC-ND 4.0 | |
| dc.subject | Literature Review | en_US |
| dc.subject | Scleroderma | en_US |
| dc.subject | Treatment | en_US |
| dc.subject | Autoimmune Disease | en_US |
| dc.subject | Human Physiology | en_US |
| dc.title | Nintedanib: A New Hope for Patients with Systemic Sclerosis-Associated Interstitial Lung Disease | |
| dc.type | Thesis/Dissertation |